中文摘要：

目的检测膀胱移行细胞癌患者血浆p14基因启动子异常甲基化状态，探讨血浆p14基因甲基化改变作为膀胱移行细胞癌分子生物学标志物的可能。方法采用甲基化特异性聚合酶链反应（methylation—specific PCR，MSP）技术，分别检测62例膀胱移行细胞癌患者血浆和相应肿瘤组织DNA的p14基因甲基化状态。结果血浆和肿瘤组织中，p14基因甲基化的阳性率分别为43．5％（27／62）和46．8％（29／62），血浆和肿瘤组织的总体符合率93．1％（27／29），血浆p14基因的甲基化状况与肿瘤组织中是否出现p14基因甲基化具有显著相关性（P〈0．01）。血浆和肿瘤组织中，p14基因甲基化与膀胱移行细胞癌的病理分级和临床分期均呈正相关。结论p14基因的甲基化状态改变在膀胱移行细胞癌的发生起重要的作用。血浆p14基因甲基化的检测是膀胱移行细胞癌诊断和判断预后的一个有效的分子生物学指标。

英文摘要：

Objective To detect hypermethylation of p14 gene in plasma DNA from patients with bladder transitional cell carcinoma and explore its potential as a biomarker. Methods Using methylationspecific PCR （MSP） ,hypermethylation of p14 gene was examined in 62 plasma samples and their corresponding tumor tissues from patients with bladder transitional cell carcinoma. Results The p14 methylation was found in 43.5% （27/62） of the plasma samples and 46.8% （29/62） of the tumor tissues. The total concordant rate of methylation status between plasma and tissue samples in p14 gene was 93.1% （2729）. There was a statistically close relationship between methylation of p14 gene in plasma and the corresponding tumor tissues （P 〈 0.01 ）. The p14 methylation in plasma and the corresponding tumor tissues was significantly correlated with the pathological types and clinical stages of the tumor. Conclusion p14 promoter may be involved in the bladder transitional cell carcinoma genesis and the presence of p14 methylated in plasma of these patients could be useful in the diagnosis and evaluating prognosis.